Clinical data
Trade names Baynas
AHFS/Drugs.com International Drug Names
Routes of
Oral (tablets)
ATC code None
Legal status
Legal status
  • Rx-only (JP)
CAS Number 116649-85-5
PubChem (CID) 123879
ChemSpider 110413
KEGG D01128
ECHA InfoCard 100.159.668
Chemical and physical data
Formula C21H21FN2O4S
Molar mass 416.46 g/mol
3D model (Jmol) Interactive image

Ramatroban (INN) is a thromboxane receptor antagonist.[1]

It is also a DP2 receptor antagonist.[2]

It is indicated for the treatment of coronary artery disease.[3] It has also been used for the treatment of asthma.[4]

It was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer and Nippon Shinyaku Co. Ltd. under the trade name Baynas.


  1. Sugimoto H, Shichijo M, Iino T, et al. (April 2003). "An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro". J. Pharmacol. Exp. Ther. 305 (1): 347–52. doi:10.1124/jpet.102.046748. PMID 12649388.
  2. Royer JF, Schratl P, Carrillo JJ, et al. (September 2008). "A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils". Eur. J. Clin. Invest. 38 (9): 663–71. doi:10.1111/j.1365-2362.2008.01989.x. PMID 18837743.
  3. Fiedler VB, Seuter F, Perzborn E (December 1990). "Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease" (PDF). Stroke. 21 (12 Suppl): IV149–51. PMID 2260140.
  4. Endo S, Akiyama K (November 1996). "[Thromboxane A2 receptor antagonist in asthma therapy]". Nippon Rinsho (in Japanese). 54 (11): 3045–8. PMID 8950952.
This article is issued from Wikipedia - version of the 8/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.